文献速递临床试验与 GCP

第二项欧洲颈动脉外科试验(ECST-2):在低至中等卒中风险的症状性与无症状性颈动脉狭窄患者中比较即刻血运重建与单纯优化药物治疗的随机临床试验的原理与方案

The 2nd European Carotid Surgery Trial (ECST-2): rationale and protocol for a randomised clinical trial comparing immediate revascularisation versus optimised medical therapy alone in patients with symptomatic and asymptomatic carotid stenosis at low to intermediate risk of stroke.
PubMed 文献 · Trials · 2022-07-27

ECST-2是一项随机对照试验,旨在验证低至中等卒中风险(5年卒中风险<20%,采用颈动脉风险评分计算)的颈动脉狭窄≥50%患者,在优化药物治疗基础上加用即刻血运重建是否获益。研究计划在入组320例有基线MRI且随访至少2年的患者后进行初期分析,主要结局为2年临床显性卒中、MRI新发脑梗死、心肌梗死或围手术期死亡的复合发生率。

要点

  • 对低至中等卒中风险的颈动脉狭窄≥50%患者,优化药物治疗基础上加用即刻血运重建的获益尚未证实。
  • 颈动脉斑块MRI特征可能有助于预测未来卒中风险并识别可从血运重建获益的亚组。
  • 初期分析计划在320例有基线MRI且随访至少2年的患者中进行。

核心结论

  • 研究假设为:颈动脉狭窄≥50%且卒中低至中等风险的患者,在接受优化药物治疗时不会从额外的颈动脉血运重建中获益。
  • 研究还假设:利用颈动脉斑块MRI结果可改善对颈动脉狭窄患者个体未来卒中风险的预测。

研究设计与样本

  • 随机临床试验,比较即刻血运重建联合优化药物治疗与单纯优化药物治疗。
  • 纳入无症状或症状性颈动脉狭窄≥50%且采用颈动脉风险评分计算的估计5年卒中风险<20%的患者。
  • 基线及随访期间进行脑MRI作为盲法评估手段,评估无症状性梗死和出血的发生率。
  • 基线时进行颈动脉斑块MRI,用于研究斑块特征决定未来卒中风险并帮助识别可从血运重建获益的亚组的假设。
  • 计划在入组320例有基线MRI且随访至少2年的患者后进行初期分析,为研究的继续或重新启动提供设计和样本量数据。

关键数值与推荐

  • 初期分析的主要结局指标为2年临床显性卒中、MRI新发脑梗死、心肌梗死或围手术期死亡的复合发生率。
  • 临床试验注册号为ISRCTN97744893,注册日期为2012年7月5日。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Carotid endarterectomy is currently recommended for patients with recently symptomatic carotid stenosis ≥50%, based on randomised trials conducted 30 years ago. Several factors such as carotid plaque ulceration, age and associated comorbidities might influence the risk-benefit ratio of carotid revascularisation. A model developed in previous trials that calculates the future risk of stroke based on these features can be used to stratify patients into low, intermediate or high risk. Since the original trials, medical treatment has improved significantly. Our hypothesis is that patients with carotid stenosis ≥50% associated with a low to intermediate risk of stroke will not benefit from additional carotid revascularisation when treated with optimised medical therapy. We also hypothesise that prediction of future risk of stroke in individual patients with carotid stenosis can be improved using the results of magnetic resonance imaging (MRI) of the carotid plaque. METHODS: Patients are randomised between immediate revascularisation plus OMT versus OMT alone. Suitable patients are those with asymptomatic or symptomatic carotid stenosis ≥50% with an estimated 5-year risk of stroke of <20%, as calculated using the Carotid Artery Risk score. MRI of the brain at baseline and during follow-up will be used as a blinded measure to assess the incidence of silent infarction and haemorrhage, while carotid plaque MRI at baseline will be used to investigate the hypotheses that plaque characteristics determine future stroke risk and help identify a subgroup of patients that will benefit from revascularisation. An initial analysis will be conducted after recruitment of 320 patients with baseline MRI and a minimum of 2 years of follow-up, to provide data to inform the design and sample size for a continuation or re-launch of the study. The primary outcome measure of this initial analysis is the combined 2-year rate of any clinically manifest stroke, new cerebral infarct on MRI, myocardial infarction or periprocedural death. DISCUSSION: ECST-2 will provide new data on the efficacy of modern optimal medical therapy alone versus added carotid revascularisation in patients with carotid stenosis at low to intermediate risk of future stroke selected by individualised risk assessment. We anticipate that the results of baseline brain and carotid plaque MRI will provide data to improve the prediction of the risk of stroke and the effect of treatment in patients with carotid stenosis. TRIAL REGISTRATION: ISRCTN registry ISRCTN97744893 . Registered on 05 July 2012.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Cheng SF, van Velzen TJ, Gregson J, et al. The 2nd European Carotid Surgery Trial (ECST-2): rationale and protocol for a randomised clinical trial comparing immediate revascularisation versus optimised medical therapy alone in patients with symptomatic and asymptomatic carotid stenosis at low to intermediate risk of stroke. Trials. 2022. PMID: 35897114. doi:10.1186/s13063-022-06429-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。